|
|
Article: Reports outline gene therapy research from Cleveland Clinic.
- Article from:
- Gene Therapy Weekly
- Article date:
- November 12, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
According to recent research published in the Journal of Biological Chemistry, "TBX5 is a T-box transcriptional factor required for cardio-genesis and limb development. TBX5 mutations cause Holt-Oram syndrome characterized by congenital heart defects and upper limb deformations."
"Here we establish a novel function for TBX5 in pre-mRNA splicing, and we show that this function is relevant to the pathogenesis of Holt-Oram syndrome, providing a novel pathogenic mechanism for the disease. Proteomics in combination with affinity purification identifies splicing factor SC35 as a candidate TBX5-associating protein. Co-immunoprecipitation and glutathione S-transferase ...
Related newspaper, magazine, and journal articles:
|
|
Article: Research conducted at Chiba Cancer Center Research Institute, ...
Cancer Gene Therapy Week;
September 29, 2008 ;
700+ words
... ... information for the Journal of Biological Chemistry is: American Society Biochemistry ... Japan, Chiba, Neuroblastoma Gene Therapy, Biochemistry, Biological Chemistry, Biotechnology, Cancer Gene Therapy, Genetics, Genomics, Hematology ...
|
|